ClinicalTrials.gg
Not yet recruitingNCT07399743Updated Feb 10, 2026

Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Knee Osteoarthritis

A Phase 3 interventional study of Alpha-Lipoic Acid (ALA)+PT and Omega-3 cap+ PT in Knee Osteoarthritis, sponsored by Badr University. Not yet recruiting. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Badr University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

Here is a **concise, clear summary (\~250 words / well under 5000 characters)** while preserving the key scientific points:

---

Knee osteoarthritis (KOA) is highly prevalent among overweight women, affecting more than 30% of those with BMI ≥25 kg/m². Excess body weight increases knee joint loading by 4-6 times per additional kilogram, accelerating cartilage degeneration, subchondral bone changes, and synovial inflammation. These alterations result in chronic pain, stiffness, functional limitation, and reduced quality of life, with obesity-related metabolic inflammation further worsening disease progression.

Standard physical therapy (PT) remains first-line treatment, yet provides only modest benefits, achieving approximately 15-20% WOMAC improvement at 12 weeks, while up to half of overweight patients continue to experience significant symptoms. Lower body positive pressure therapy (LBPP) via antigravity treadmill offers a biomechanical enhancement by unloading 40-80% of body weight, enabling pain-free gait training and reducing joint impact forces by up to 80%. Studies report 30-40% WOMAC improvement and better walking capacity compared with conventional PT.

Nevertheless, mechanical interventions alone do not address the inflammatory and oxidative mechanisms driving KOA. Alpha-lipoic acid (600 mg/day) and omega-3 fatty acids (1.5-2 g/day) provide targeted biochemical modulation, reducing pro-inflammatory cytokines, oxidative stress, and cartilage-degrading enzymes, with reported 25-35% functional improvement in clinical trials.

Despite the promise of both approaches, no randomized trial has directly compared adding LBPP versus combined ALA and omega-3 supplementation to standard PT in overweight women with KOA. This study aims to fill this gap by evaluating the relative effectiveness of biomechanical versus biochemical adjuncts to optimize management of KOA in this high-risk population.

02

Conditions studied

  • Knee Osteoarthritis
03

In context

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 160 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Badr University is the lead sponsor of 64 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants aged between 20-45 years.

    1. Their ranged between 20-25 kg/m².
    2. All had radiographic confirmation of mild to moderate knee osteoarthritis.
    3. Medical history recorded with no major prior injuries or surgeries affecting outcomes.
    4. Participants reported knee pain, functional limitation, and activity-related symptoms.
    5. Radiographic grading confirmed as Kellgren-Lawrence grade II or III.

Exclusion criteria

Exclusion criteria:

  1. No recent traumatic hip, knee, or ankle surgery within the past 6 months.
  2. No severe knee OA (Kellgren-Lawrence grade 0 or 4).
  3. No history of rheumatoid arthritis, chronic reactive arthritis, or psoriatic arthritis.
  4. Free from conditions that limit safe study participation or adherence to protocol.
  5. No neurological impairments affecting lower limb function.
  6. No to exercise or physiotherapy (e.g., severe cardiovascular, respiratory, or metabolic conditions).
  7. Not pregnant or planning pregnancy during the study.
  8. Not involved in other clinical trials or conflicting interventions (e.g., intra-articular injections, surgery, or rehab programs).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    ALA tab 300 mg BID (Thioctacid) + PT

    Drug: Alpha-Lipoic Acid (ALA)+PT

  • Active comparator
    Omega-3 cap 2000 mg BID (Limitless Omega) + PT

    Drug: Omega-3 cap+ PT

  • Active comparator
    LBPP (AlterG 40-60% unload, 30 min 3×/week) + PT

    Device: Lower body positive pressure therapy (LBPP)+PT

  • Active comparator
    PT

    Device: Standard physical therapy (PT)

Interventions

  • DrugAlpha-Lipoic Acid (ALA)+PT

    Drug page: Thioctic AcidStudies of Thioctic AcidThioctic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Thioctacid 600+PT

  • DrugOmega-3 cap+ PT

    Omega-3 cap 2000 mg BID (Limitless Omega) + PT

  • DeviceLower body positive pressure therapy (LBPP)+PT

    LBPP: AlterG 40-60% unload, 30 min (3×/week) + PT

  • DeviceStandard physical therapy (PT)

    PT typically includes quadriceps strengthening, flexibility exercises, proprioceptive training, stationary cycling, and aquatic therapy

06

What researchers measure

Primary outcomes

  1. Change in VAS pain score (0-10 cm)

    Time frame: from baseline to 12 weeks

  2. Change in WOMAC total score (0-96)

    Time frame: from baseline to 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jun 2026, 3 months later.

Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 3 months is below that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartEst.
Feb 15, 2026
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jul 1, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07399743
Lead sponsor
Badr University
Responsible party
Eman Said Sawan (Lecturer, Badr University) — Principal investigator
First posted
Feb 10, 2026
Start date
Feb 15, 2026 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Feb 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thioctic Acid

Start the discussion